Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ripretinib (DCC-2618) is an orally bioavailable inhibitor of KIT and PDGFRA.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 68.00 | |
2 mg | In stock | $ 98.00 | |
5 mg | In stock | $ 168.00 | |
10 mg | In stock | $ 289.00 | |
25 mg | In stock | $ 492.00 | |
50 mg | In stock | $ 717.00 | |
100 mg | In stock | $ 987.00 | |
500 mg | In stock | $ 1,980.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 213.00 |
Description | Ripretinib (DCC-2618) is an orally bioavailable inhibitor of KIT and PDGFRA. |
Synonyms | DCC-2618 |
Molecular Weight | 510.36 |
Formula | C24H21BrFN5O2 |
CAS No. | 1442472-39-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 40 mg/mL(78.38 mM), Sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ripretinib 1442472-39-0 Angiogenesis Apoptosis Tyrosine Kinase/Adaptors FLT VEGFR c-Kit PDGFR Inhibitor Vascular endothelial growth factor receptor CD135 CD117 DCC-2618 Platelet-derived growth factor receptor inhibit Cluster of differentiation antigen 135 SCFR Fms like tyrosine kinase 3 FLT3 DCC2618 DCC 2618 inhibitor